Compositions comprising rank/rankl antagonists and related compounds for treating pain
View Patent ↗Disclosed herein are method of treating pain using comprising RANK/RANKL antagonists.
1. A method of treating pain comprising administering a polypeptide or a protein to relieve pain in a mammal in need thereof, wherein the polypeptide or the protein is a RANK/RANKL antagonist, wherein the pain is osteoarthritis pain and the RANK/RANKL antagonist is denosumab.
2. The method of claim 1 , wherein, within a period of about six months, about 0.1 mg/kg to about 20 mg/kg of denosumab is administered to the mammal.
3. The method of claim 1 , wherein, within a period of about six months, about 0.5 mg/kg to about 2 mg/kg of denosumab is administered to the mammal.
4. The method of claim 3 , wherein the denosumab is administered once every six months.
5. The method of claim 1 , wherein the mammal is a human being.
6. The method of claim 1 , wherein the pain is associated with osteoarthritis of the knee.
7. The method of claim 1 , wherein the osteoarthritis affects a knee or hip.
8. The method of claim 1 , wherein the osteoarthritis affects an elbow, a shoulder, a wrist, or a finger.
9. A method of treating pain comprising administering a polypeptide or a protein to relieve pain in a mammal in need thereof, wherein the polypeptide or the protein is a RANK/RANKL antagonist, wherein the pain is complex regional pain syndrome and the RANK/RANKL antagonist is denosumab.
10. The method of claim 9 , wherein, within a period of about six months, about 0.1 mg/kg to about 20 mg/kg of denosumab is administered to the mammal.
11. The method of claim 9 , wherein, within a period of about six months, about 0.5 mg/kg to about 2 mg/kg of denosumab is administered to the mammal.
12. The method of claim 11 , wherein the denosumab is administered once every six months.
13. The method of claim 9 , wherein the mammal is a human being.
14. A method of treating pain comprising administering a polypeptide or a protein to relieve pain in a mammal in need thereof, wherein the polypeptide or the protein is a RANK/RANKL antagonist, wherein the pain is low back pain and the RANK/RANKL antagonist is denosumab.
15. The method of claim 14 , wherein the pain is chronic low back pain.
16. The method of claim 14 , wherein the low back pain is associated with Modic changes.
17. The method of claim 14 , wherein, within a period of about six months, about 0.1 mg/kg to about 20 mg/kg of denosumab is administered to the mammal.
18. The method of claim 14 , wherein, within a period of about six months, about 0.5 mg/kg to about 2 mg/kg of denosumab is administered to the mammal.
19. The method of claim 18 , wherein the denosumab is administered once every six months.
20. The method of claim 14 , wherein the mammal is a human being.